Fig. 1From: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE studyCumulative risk of primary outcomes among PS-matched initiators of empagliflozin vs. GLP-1RACAPTION: The risks of cardiovascular mortality, MACE, and HHF were lower in the empagliflozin vs. GLP-1RA initiators. Cardiovascular mortality data was only available in the Medicare databaseCV: cardiovascular; GLP-1RA: Glucagon-like peptide-1 receptor agonists; MACE: major adverse cardiovascular events; PS: propensity scoreBack to article page